Table 1.
Milestones for patients with CP-CML treated with tyrosine kinase inhibitors.
| European Leukemia Net (2020) | |||
|---|---|---|---|
| Optimal | Warning | Failure | |
| 3 months | BCR::ABL1 ≤10% | BCR::ABL1 >10% | BCR::ABL1 >10% if confirmed within 1–3 months |
| 6 months | BCR::ABL1 ≤1% | BCR::ABL1 >1–10% | BCR::ABL1 >10% |
| 12 months | BCR::ABL1 ≤0.1% | BCR::ABL1 >0.1–1% | BCR::ABL1 >1% |
| Any time | BCR::ABL1 ≤0.1% | BCR::ABL1 >0.1–1%, loss of MMR | BCR::ABL1 >1%, resistance mutations, high-risk ACA |
| National Comprehensive Cancer Network (2023) | |||
|---|---|---|---|
| TKI-sensitive | Possible TKI-resistant | TKI-resistant | |
| 3 months | BCR::ABL1 ≤10% | BCR::ABL1 >10% | |
| 6 months | BCR::ABL1 ≤10% | BCR::ABL1 >10% | |
| 12 months | BCR::ABL1 ≤1% | BCR::ABL1 1–10% | BCR::ABL1 >1% |
| European Society for Medical Oncology (2017) | |||
|---|---|---|---|
| Optimal | Warning | Failure | |
| 3 months | Ph ≤35%, BCR::ABL1 <10% | Ph 36–95%, BCR::ABL1 >10% | No CHR, Ph >95% |
| 6 months | Ph 0%, BCR::ABL1 <1% | Ph 1–65%, BCR::ABL1 1–10% | Ph >35%, BCR::ABL1 >10% |
| 12 months | BCR::ABL1 <0.1% | BCR::ABL1 0.1–1% | Ph ≥1%, BCR::ABL1 >1% |
| >18 months | BCR::ABL1 <0.01% | BCR::ABL1 0.1–1% | |
| Any time | Relapse, loss of MMR | ||
Abbreviations: ACA, additional chromosomal abnormality; CHR, complete hematological response; MMR, major molecular response; Ph, Philadelphia chromosome-positive; TKI, tyrosine kinase inhibitor.